Drugs / CGC-11047
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00446654 | Apr → Oct 2007 | age-related macular degeneration | Progen Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00705874 | May 2006 → Aug 2011 | cancer | Progen Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00585416 | Jun 2006 → Nov 2007 | prostate cancer | University of Wisconsin, Madison | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGC-11047 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00446654 ↗ |
| Route | Other | “16.5 mg (3.3%) subconjunctival injection” NCT00446654 ↗ |